Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Albireo Pharma Inc.
Headquarters: Boston, MA, United States of America
Website: N/A
Year Founded: 2003
Status: Acquired
BioCentury | Aug 20, 2024
Management Tracks
Toraishi steps down from Rakuten Medical as co-CEO
Plus: SalioGen hired Kalliopi Stasi as CMO and updates from PepGen, Cidara and Bio-Rad
BioCentury | Jun 12, 2024
Management Tracks
Former Fusion CFO Crowley joins Centessa
Weinhoff becomes CBO. Plus: QurAlis pads C-suite and updates from PepGen, C4 and more
BioCentury | Feb 27, 2024
Management Tracks
Pamela Stephenson to head commercial at Disc
Plus: Seres names Marella Thorell as CFO, and updates from Diakonos and NRx
BioCentury | Dec 19, 2023
Deals
Dec. 18 Quick Takes: Illumina to divest Grail
Plus: Pivotal closes $389M Partners Fund II and updates from Novo Nordisk Foundation, Mirum, Santhera, Arcutis and Checkpoint
BioCentury | Nov 2, 2023
Management Tracks
Sam Raha named COO at Myriad
Plus: Endeavor hires a new CMO, and updates from Jasper, Syantra, Ocuphire, Senisca and more
BioCentury | Aug 22, 2023
Management Tracks
Mark McKenna named chairman at Apogee
Plus: Harford becomes CFO of Amicus, and updates from Ray and Adverum
BioCentury | Jan 23, 2023
Deals
CinCor, Albireo each received higher bids in 2022 before this month’s M&A deals
Biotechs had sweeter offers, then accepted smaller proposals after share prices fell
BioCentury | Jan 13, 2023
Deals
J.P. Morgan deal wrap: European buyers, RNA and gene editing in spotlight
Takeouts feature CVRs to balance regulatory risk, while appetite for research collaborations remains strong in newer modalities
BioCentury | Jan 10, 2023
Deals
JPM highlights & Alzheimer’s takeaways
Deals and stormy sentiments at biopharma’s annual kickoff, plus hot takes from CERSI, neuroscience meetings
BioCentury | Jan 9, 2023
Deals
Chiesi bolsters rare disease portfolio via $1.3B Amryt buyout
Italian pharma becomes latest home for therapies Amryt obtained in 2019 merger with Aegerion; deal has CVRs tied to rare skin disease therapy
Items per page:
1 - 10 of 45